Zacks Research Comments on Medifast’s Q2 Earnings (NYSE:MED)

Medifast, Inc. (NYSE:MED) – Analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for Medifast in a research report issued to clients and investors on Monday, March 10th. Zacks Research analyst R. Department now expects that the specialty retailer will post earnings per share of $0.24 for the quarter, down from their previous estimate of $0.29. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.32 EPS, Q2 2026 earnings at $0.32 EPS, FY2026 earnings at $1.52 EPS and FY2027 earnings at $2.08 EPS.

Medifast (NYSE:MED) last announced its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.26. The business had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. Medifast had a net margin of 0.35% and a return on equity of 10.64%.

Separately, DA Davidson decreased their price target on Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th.

Medifast Trading Down 1.4 %

Shares of MED stock opened at $13.86 on Wednesday. The stock has a 50 day simple moving average of $15.25 and a 200-day simple moving average of $17.43. The company has a market cap of $151.56 million, a price-to-earnings ratio of 76.98 and a beta of 1.13. Medifast has a 12-month low of $13.57 and a 12-month high of $39.14.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Prescott Group Capital Management L.L.C. acquired a new position in Medifast in the fourth quarter worth $1,938,000. Marshall Wace LLP bought a new stake in Medifast in the fourth quarter worth about $1,836,000. Two Sigma Advisers LP lifted its position in shares of Medifast by 86.0% during the 4th quarter. Two Sigma Advisers LP now owns 216,000 shares of the specialty retailer’s stock valued at $3,806,000 after acquiring an additional 99,900 shares during the last quarter. Federated Hermes Inc. raised its holdings in Medifast by 28.8% during the 4th quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer’s stock worth $4,924,000 after buying an additional 62,574 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Medifast by 103.9% in the 4th quarter. JPMorgan Chase & Co. now owns 117,157 shares of the specialty retailer’s stock valued at $2,064,000 after purchasing an additional 59,702 shares during the period. 95.51% of the stock is owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.